Report Detail

Other Global Myasthenia Gravis Disease Treatment Market Size, Status and Forecast 2019-2025

  • RnM3472121
  • |
  • 12 July, 2019
  • |
  • Global
  • |
  • 97 pages
  • |
  • QYResearch
  • |
  • Other

Global Myasthenia Gravis Disease Treatment Market Size, Status and Forecast 2019-2025

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Myasthenia Gravis Disease Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Medication
      • 1.4.3 Surgery
      • 1.4.4 Others
    • 1.5 Market by Application
      • 1.5.1 Global Myasthenia Gravis Disease Treatment Market Share by Application (2014-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Myasthenia Gravis Disease Treatment Market Size
    • 2.2 Myasthenia Gravis Disease Treatment Growth Trends by Regions
      • 2.2.1 Myasthenia Gravis Disease Treatment Market Size by Regions (2014-2025)
      • 2.2.2 Myasthenia Gravis Disease Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Myasthenia Gravis Disease Treatment Market Size by Manufacturers
      • 3.1.1 Global Myasthenia Gravis Disease Treatment Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Myasthenia Gravis Disease Treatment Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Myasthenia Gravis Disease Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Myasthenia Gravis Disease Treatment Key Players Head office and Area Served
    • 3.3 Key Players Myasthenia Gravis Disease Treatment Product/Solution/Service
    • 3.4 Date of Enter into Myasthenia Gravis Disease Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Myasthenia Gravis Disease Treatment Market Size by Type (2014-2019)
    • 4.2 Global Myasthenia Gravis Disease Treatment Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Myasthenia Gravis Disease Treatment Market Size (2014-2019)
    • 5.2 Myasthenia Gravis Disease Treatment Key Players in United States
    • 5.3 United States Myasthenia Gravis Disease Treatment Market Size by Type
    • 5.4 United States Myasthenia Gravis Disease Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Myasthenia Gravis Disease Treatment Market Size (2014-2019)
    • 6.2 Myasthenia Gravis Disease Treatment Key Players in Europe
    • 6.3 Europe Myasthenia Gravis Disease Treatment Market Size by Type
    • 6.4 Europe Myasthenia Gravis Disease Treatment Market Size by Application

    7 China

    • 7.1 China Myasthenia Gravis Disease Treatment Market Size (2014-2019)
    • 7.2 Myasthenia Gravis Disease Treatment Key Players in China
    • 7.3 China Myasthenia Gravis Disease Treatment Market Size by Type
    • 7.4 China Myasthenia Gravis Disease Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Myasthenia Gravis Disease Treatment Market Size (2014-2019)
    • 8.2 Myasthenia Gravis Disease Treatment Key Players in Japan
    • 8.3 Japan Myasthenia Gravis Disease Treatment Market Size by Type
    • 8.4 Japan Myasthenia Gravis Disease Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Myasthenia Gravis Disease Treatment Market Size (2014-2019)
    • 9.2 Myasthenia Gravis Disease Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Myasthenia Gravis Disease Treatment Market Size by Type
    • 9.4 Southeast Asia Myasthenia Gravis Disease Treatment Market Size by Application

    10 India

    • 10.1 India Myasthenia Gravis Disease Treatment Market Size (2014-2019)
    • 10.2 Myasthenia Gravis Disease Treatment Key Players in India
    • 10.3 India Myasthenia Gravis Disease Treatment Market Size by Type
    • 10.4 India Myasthenia Gravis Disease Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Myasthenia Gravis Disease Treatment Market Size (2014-2019)
    • 11.2 Myasthenia Gravis Disease Treatment Key Players in Central & South America
    • 11.3 Central & South America Myasthenia Gravis Disease Treatment Market Size by Type
    • 11.4 Central & South America Myasthenia Gravis Disease Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 GlaxoSmithKline
      • 12.1.1 GlaxoSmithKline Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Myasthenia Gravis Disease Treatment Introduction
      • 12.1.4 GlaxoSmithKline Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
      • 12.1.5 GlaxoSmithKline Recent Development
    • 12.2 Novartis
      • 12.2.1 Novartis Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Myasthenia Gravis Disease Treatment Introduction
      • 12.2.4 Novartis Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
      • 12.2.5 Novartis Recent Development
    • 12.3 Teva Pharmaceutical
      • 12.3.1 Teva Pharmaceutical Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Myasthenia Gravis Disease Treatment Introduction
      • 12.3.4 Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
      • 12.3.5 Teva Pharmaceutical Recent Development
    • 12.4 Roche
      • 12.4.1 Roche Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Myasthenia Gravis Disease Treatment Introduction
      • 12.4.4 Roche Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
      • 12.4.5 Roche Recent Development
    • 12.5 Bristol-Myers Squibb
      • 12.5.1 Bristol-Myers Squibb Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Myasthenia Gravis Disease Treatment Introduction
      • 12.5.4 Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
      • 12.5.5 Bristol-Myers Squibb Recent Development
    • 12.6 Apotex
      • 12.6.1 Apotex Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Myasthenia Gravis Disease Treatment Introduction
      • 12.6.4 Apotex Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
      • 12.6.5 Apotex Recent Development
    • 12.7 Cipla
      • 12.7.1 Cipla Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Myasthenia Gravis Disease Treatment Introduction
      • 12.7.4 Cipla Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
      • 12.7.5 Cipla Recent Development
    • 12.8 Biogen
      • 12.8.1 Biogen Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Myasthenia Gravis Disease Treatment Introduction
      • 12.8.4 Biogen Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
      • 12.8.5 Biogen Recent Development
    • 12.9 AbbVie
      • 12.9.1 AbbVie Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Myasthenia Gravis Disease Treatment Introduction
      • 12.9.4 AbbVie Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
      • 12.9.5 AbbVie Recent Development
    • 12.10 Valeant Pharmaceuticals
      • 12.10.1 Valeant Pharmaceuticals Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Myasthenia Gravis Disease Treatment Introduction
      • 12.10.4 Valeant Pharmaceuticals Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
      • 12.10.5 Valeant Pharmaceuticals Recent Development
    • 12.11 Sun Pharmaceuticals
    • 12.12 Fresenius Kabi
    • 12.13 Piramal Healthcare
    • 12.14 RPG Life Sciences

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.
      The Americas accounted for the largest market share of the global myasthenia gravis disease market owing to the growing number of drug manufacturers, increasing awareness about the long-term effects of muscle dystrophy, and rising government funding for the treatment of this disease in the region. Moreover, the U.S. contributes to a significant market share in the global pharmaceutical industry.
      In 2018, the global Myasthenia Gravis Disease Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Myasthenia Gravis Disease Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Myasthenia Gravis Disease Treatment development in United States, Europe and China.

      The key players covered in this study
      GlaxoSmithKline
      Novartis
      Teva Pharmaceutical
      Roche
      Bristol-Myers Squibb
      Apotex
      Cipla
      Biogen
      AbbVie
      Valeant Pharmaceuticals
      Sun Pharmaceuticals
      Fresenius Kabi
      Piramal Healthcare
      RPG Life Sciences

      Market segment by Type, the product can be split into
      Medication
      Surgery
      Others

      Market segment by Application, split into
      Hospitals
      Clinics
      Others

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Myasthenia Gravis Disease Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Myasthenia Gravis Disease Treatment development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Myasthenia Gravis Disease Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


      Summary:
      Get latest Market Research Reports on Myasthenia Gravis Disease Treatment. Industry analysis & Market Report on Myasthenia Gravis Disease Treatment is a syndicated market report, published as Global Myasthenia Gravis Disease Treatment Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Myasthenia Gravis Disease Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,137.42
      4,706.13
      6,274.83
      3,474.24
      5,211.36
      6,948.48
      421,777.20
      632,665.80
      843,554.40
      268,194.03
      402,291.05
      536,388.06
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report